Co-D Therapeutics

Co-D Therapeutics

Navigation

  • About Co-D
    • Mission & Vision
    • Management
    • Board of Directors
    • Advisory Board
    • Career Opportunities
  • Technology
    • Combination Therapy
  • Pipeline
    • Triolimus
  • Partnering
  • News & Events
    • Co-D in the News
    • Press Releases
    • Events
    • Publications
    • Presentations
  • Contact Us
You are here: Home > FDA grants orphan drug status to Madison company’s drug treatment
  • April 28, 2015
  • Abdalla Saad

FDA grants orphan drug status to Madison company’s drug treatment

Categories: News

Madison-based Co-D Therapeutics Inc. said Tuesday the U.S. Food and Drug Administration has granted orphan drug status for a drug it is developing for the treatment of a rare cancer of the inner lining of blood vessels. The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the U.S. With the designation, Co-D will be able to run smaller clinical trials, receive tax credits, seven years of market exclusivity after market approval and other benefits.

← Expression of angiopoietin-TIE system components in angiosarcoma
Co-D Therapeutics Granted Orphan Designation for Triolimus for the Treatment of Angiosarcoma →
  • Home
  • About Co-D
  • Technology
  • Pipeline
  • Partnering
  • News & Events
  • Contact Us

Recent Posts

  • Co-D Therapeutics accepted into NCL Laboratory Assay Cascade characterization and testing program
  • Nanoparticles Improve Tumor Treatment in Mice
  • Improving Cancer Diagnosis and Treatment
  • Madison startup advances three-in-one cancer drug rooted at UW
  • Co-D Therapeutics Granted Orphan Designation for Triolimus for the Treatment of Angiosarcoma
Co-D Therapeutics © 2013-2018. All Rights Reserved.                          Home | About Co-D | Technology | Pipeline | Partnering | News & Events | Careers | Contact Us